TNF inhibitor safety
Executive Summary
Safety of tumor necrosis factor inhibitors and a possible link to lymphoma will be discussed by FDA's Arthritis Drugs Advisory Committee March 4. The committee will receive safety updates on all three marketed TNF inhibitors - Amgen's Enbrel, Centocor's Remicade and Abbott's Humira. The committee's TNF inhibitor safety review in August 2001 focused on the risk of immune disorders (1"The Pink Sheet" Aug. 20, 2001, p. 7)...
You may also be interested in...
Amgen Enbrel Focus Includes Push For Earlier Treatment Of RA Patients
Amgen's marketing strategy for Enbrel (etanercept) includes closing the gap between diagnosis and initiation of therapy in patients with moderate rheumatoid arthritis
Centocor Remicade Black Box MD Visits Will Be 85% Complete By Aug. 31
Centocor sales representatives will visit 85% of targeted Remicade prescribers by the end of August to inform them of a new black box warning added to labeling for the rheumatoid arthritis therapy, Exec Director-Medical Affairs Tom Schaible, PhD, told the FDA Arthritis Advisory Committee.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.